Showing 2671-2680 of 3392 results for "".
- Stelara Approved for PsO in Kids Ages 6-11https://practicaldermatology.com/news/stelara-approved-for-pso-in-kids-ages-6-11/2460482/Stelara® (ustekinumab) is now approved for pediatric patients (6-11 years of age) with moderate to severe plaque psoriasis (PsO). Stelara, from The Janssen Pharmaceutical Companies of Johnson & Johnson, targets both interleukin (IL)-12 and IL-23
- Another New Patent for Alastin Skincarehttps://practicaldermatology.com/news/another-new-patent-for-alastin-skincare/2460473/Alastin Skincare, Inc. received a fourth U.S. Patent from the United States Patent and Trademark Office. The new patent, which incorporates TriHex Technology, is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum
- Tremfya is First IL-23 Inhibitor Approved for PsAhttps://practicaldermatology.com/news/tremfya-is-first-il-23-inhibitor-approved-for-psa/2460471/FDA has approved Tremfya® (guselkumab) from Janssen Pharmaceutical Companies of Johnson & Johnson for adult patients with active psoriatic arthritis (PsA). Tremfya is the first interleukin (IL)-23 approved for active PsA. The safety and efficacy of
- Physician-Created App Unveils Remote Check-In Feature to Prevent Spread of COVID-19 in Medical Practiceshttps://practicaldermatology.com/news/physician-created-app-unveils-remote-check-in-feature-to-prevent-spread-of-covid-19-in-medical-practices/2460436/DocClocker, an app that allows patients to receive real-time wait time reporting of their medical providers, enabling patients to avoid long waits in medical waiting rooms—limiting COVID-19 exposure risks. The company recently launched a new feature for the app—DocClocker Remote Check
- New Phase 3 Data for Tremfya Show Consistent, High Levels of Skin Clearance Through Four Years in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-phase-3-data-for-tremfya-show-consistent-high-levels-of-skin-clearance-through-four-years-in-moderate-to-severe-plaque-psoriasis/2460431/New long-term plaque psoriasis data for The Janssen Pharmaceutical Companies of Johnson & Johnson's Tremfya (guselkumab) show consistent, high levels of skin clearance at week 100 and week 204 (four years). In the open-label extension of VOYAGE 2, at four years, 80 percent of pa
- Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weekshttps://practicaldermatology.com/news/late-breaking-data-show-skyrizi-achieves-superior-rates-of-complete-skin-clearance-for-psoriasis-compared-to-secukinumab-at-52-weeks/2460423/New late-breaking Phase 3b head-to-head data show superior rates of skin clearance for AbbVie's risankizumab-rzaa (Skyrizi) compared to secukinumab (Cosentyx) at week 52. Sixty-six percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in th
- Crayola Announces New "Colors of the World" Crayons To Help Advance "Skinclusion"https://practicaldermatology.com/news/crayola-announces-new-colors-of-the-world-crayons-to-help-advance-skinclusion/2460402/Crayola is launching Colors of the World crayons—24 new crayons designed to represent more than 40 global skin tones across the world. The crayon packs feature side panels that serve as color references. Each crayon is wrapped in a gradient skin tone label with the color
- AAD Survey: Most Americans Know Sun Protection Is Important, Still Don't Protect Themselveshttps://practicaldermatology.com/news/aad-survey-most-americans-know-sun-protection-is-important-but-still-dont-protect-themselves-1/2460367/Fully 76 percent of Americans agree that sun protection is an important healthy habit, yet only 41 percent report regularly protecting themselves outdoors — increasing their risk for skin cancer, according to a new survey from the American Academy of Dermatology. What’s more
- Revian Awarded Patent for Biostimulatory Light Combinationshttps://practicaldermatology.com/news/revian-awarded-patent-for-biostimulatory-light-technology/2460249/Revian Inc. has received from the United States Patent and Trademark Office (USPTO) U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the u
- Straight Up: Paula Abdul Is InMode's New Brand Ambassadorhttps://practicaldermatology.com/news/straight-up-paula-abdul-is-inmodes-new-brand-ambassador/2460122/Paula Abdul is InMode’s new brand ambassador for BodyTite, FaceTite and Morpheus8 technologies. As a lifelong performer, Abdul has always taken care of herself and has the muscles to prove it—however, at age 57, she acknowledg